Investment Rating - The report assigns a "Buy" rating for the company, marking the first coverage of the stock [1]. Core Insights - The company, Zhejiang Jinhua New Materials Co., Ltd., is a leading supplier of ketoxime products and has established a strong position in the fine chemical industry, particularly in silane crosslinking agents and hydroxylamine salts [9][14]. - The hydroxylamine salt market is expanding, driven by increased demand in downstream industries such as agriculture, pharmaceuticals, and electronics, which opens up long-term growth opportunities for the company [9][40]. - The company has a robust technical innovation capability and a rich customer base, including partnerships with major international and domestic chemical companies [9][57]. Summary by Sections 1. Company Overview - Zhejiang Jinhua New Materials specializes in the R&D, production, and sales of ketoxime series fine chemicals, including silane crosslinking agents and hydroxylamine salts [9][14]. - The company has received numerous accolades, including being recognized as a national "little giant" enterprise and a high-tech enterprise [14]. 2. Market Dynamics - The fine chemical industry is a strategic focus in China's chemical sector, with hydroxylamine salts being a key raw material for various applications, including low-toxicity pesticides and high-efficiency metal extractants [40][39]. - The global hydroxylamine salt market is projected to grow from 2.714 billion yuan in 2023 to 3.179 billion yuan by 2028, with a CAGR of 3.21% [40][41]. 3. Technical Innovation and Customer Base - The company has established a green circular industrial chain for ketoxime products, showcasing its commitment to sustainable practices and innovation [16][57]. - Jinhua New Materials has built a strong customer network, including partnerships with Bayer and domestic leaders like Wanhua Chemical, ensuring a stable demand for its products [60][57]. 4. Financial Projections - The company is expected to achieve revenues of 1.064 billion yuan in 2025, with a projected net profit of 198.77 million yuan, reflecting a growth trajectory despite a slight decline in 2025 [1][21]. - The earnings per share (EPS) are forecasted to be 1.47 yuan in 2025, with a P/E ratio of 34.00, indicating a favorable valuation compared to peers [1][21].

[Table_Tag] [Table_Summary] 投资要点 证券研究报告·北交所公司深度报告·化学制品 锦华新材（920015） 精细化工基石稳固，电子化学品崭露头角 2026 年 02 月 03 日 买入（首次） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 1,115 | 1,239 | 1,064 | 1,209 | 1,507 | | 同比（%） | 12.13 | 11.21 | (14.18) | 13.67 | 24.63 | | 归母净利润（百万元） | 172.51 | 210.94 | 198.77 | 257.08 | 344.23 | | 同比（%） | 116.74 | 22.28 | (5.77) | 29.33 | 33.90 | | EPS-最新摊薄（元/股） | 1.27 | 1.56 | 1.47 | 1.90 | 2.54 | | P/E（现价&最新摊薄） | 39.17 | 32 ...

[Table_Page] 公司深度研究|汽车服务 [Table_Title] 中国汽研（601965.SH） 卡位稀缺，受益于中国汽车标准做大做强 [Table_Summary] 核心观点： 盈利预测： | [Table_ 单位 Finance] :人民币百万元 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入 | 4,007 | 4,697 | 4,967 | 5,866 | 7,171 | | 增长率（ % ） | 21.8% | 17.2% | 5.8% | 18.1% | 22.3% | | EBITDA | 1,306 | 1,678 | 1,956 | 2,278 | 2,673 | | 归母净利润 | 825 | 908 | 1,060 | 1,216 | 1,466 | | 增长率（ % ） | 19.7% | 10.0% | 16.8% | 14.7% | 20.6% | | EPS（元/股） | 0.82 | 0.90 | 1.06 | 1.21 | 1.46 | | ...

2026 年 02 月 03 日 中际旭创(300308.SZ) 红利 事件： 1 月 31 日，中际旭创发布全年业绩预告，公司预计 2025 年 1-12 月 业绩大幅上升，归属于上市公司股东的净利润为 98.00 亿至 118.00 亿，净利润同比增长 89.50%至 128.17%。公司预测业绩增长主要基 于：受益于算力需求，高速光模块等产品出货增加带动营收和利润提 升。虽然股份支付费用、存货与应收款减值损失、汇率下跌带来的汇 兑损失共计减少净利润约 6.06 亿元，但投资收益与公允价值变动损 益增加了净利润约 2.96 亿元，部分抵消了上述负面影响。 全球市场高速增长，需求远超供给: 全球 AI 算力建设正推动高端光模块需求高速增长，市场呈现"需求 远超供给"的紧平衡状态。根据 Lightcounting 预计，由于海内外科 技巨头（如 Alphabet、亚马逊、Meta、微软、阿里巴巴、腾讯、百度 等）创纪录的资本支出，当前包括光模块在内的许多产品需求超出供 应两倍以上。未来市场增速将直接取决于供应链的扩产能力。 增长的核心动力明确：一是 AI 基础设施对高速光模块与交换机的强 劲需求；二是光互连技 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 53.84 CNY [4][7]. Core Insights - The company's short-term performance is under pressure due to intensified competition and policy impacts, leading to a downward revision of revenue and profit forecasts for 2025-2026 [4][10]. - Despite the short-term challenges, the company has significant long-term growth potential driven by self-research and innovation transformation [4][10]. - The company is expected to leverage its integrated service capabilities in contract research and development (CRO) and contract development and manufacturing organization (CDMO) to enhance its business structure and return to a growth trajectory [10]. - The company has a robust pipeline of self-researched products, with 132 projects under development, including 37 approved products, which are anticipated to contribute to stable revenue growth as they enter commercialization [10]. - The company is actively transitioning to innovative drug development, with 15 ongoing projects in key therapeutic areas, which could provide a second growth curve through partnerships and milestone payments [10]. Financial Summary - Revenue is projected to decline from 1,017 million CNY in 2023 to 696 million CNY in 2025, with a recovery to 889 million CNY by 2027 [6]. - The net profit attributable to the parent company is expected to turn negative in 2024 and 2025, with forecasts of -53 million CNY and -69 million CNY respectively, before recovering to 67 million CNY in 2027 [6]. - The earnings per share (EPS) is forecasted to be -0.63 CNY in 2025, with a recovery to 0.61 CNY by 2027 [6]. - The gross margin is expected to decrease from 65.5% in 2023 to 52.0% in 2024, before gradually improving to 56.4% by 2027 [6].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The issuance of H-share zero-coupon convertible bonds is expected to dilute H-share capital by 29.53% and total capital by 5.6%, with proceeds aimed at overseas business development and working capital supplementation. This is anticipated to have short-term pressure on the stock price, particularly in the Hong Kong market, but is expected to benefit long-term international business growth and enhance overall ROE [4][5][6] - The company maintains its profit forecast, projecting net profit attributable to shareholders of 168 billion, 217 billion, and 251 billion yuan for 2025-2027, representing year-on-year growth of 9%, 29%, and 16% respectively. The corresponding PE ratios are 12.2, 9.4, and 8.2 times, with a current PB of 1.20 times [4][6] Financial Summary - Revenue is projected to reach 37,078 million yuan in 2025, with a year-on-year decrease of 10.6%, followed by a recovery to 43,144 million yuan in 2026 and 48,837 million yuan in 2027, with growth rates of 16.4% and 13.2% respectively [7][10] - Net profit attributable to shareholders is expected to be 16,750 million yuan in 2025, 21,680 million yuan in 2026, and 25,067 million yuan in 2027, with year-on-year growth rates of 9.1%, 29.4%, and 15.6% respectively [7][10] - The company's gross margin is projected to improve from 51.2% in 2025 to 58.5% in 2027, while the net margin is expected to rise from 45.2% to 51.3% over the same period [7][10] Valuation Metrics - The projected PE ratios for the company are 12.2 for 2025, 9.4 for 2026, and 8.2 for 2027, indicating a favorable valuation trend [7][10] - The projected PB ratios are 1.2 for 2025, 1.1 for 2026, and 1.0 for 2027, suggesting a decreasing trend in the price-to-book ratio [7][10]

Investment Rating - The report assigns a "Buy" rating for the company, indicating a positive outlook following the divestiture of its real estate business and steady growth in the cosmetics segment [5][42]. Core Insights - The company has transitioned its main business focus to cosmetics and pharmaceuticals after divesting its real estate operations in 2023. The cosmetics segment has shown resilience, contributing over 52.8% of total revenue [10][41]. - The company is leveraging a "product + R&D + channel" strategy to build competitive advantages, focusing on marketing synergies, innovation in product development, and a comprehensive online and offline sales network [8][30][34]. - Revenue projections for 2025-2027 are estimated at RMB 38.1 billion, RMB 39.3 billion, and RMB 43.0 billion, with corresponding growth rates of -4.3%, +3.1%, and +9.5% respectively. Net profit is expected to reach RMB 2.4 billion, RMB 2.7 billion, and RMB 3.1 billion during the same period [9][41]. Summary by Sections Market Performance - The closing price of the stock is RMB 7.36, with a total market capitalization of RMB 7,481.95 million and a circulating market value of RMB 7,481.95 million [3]. Financial Data - The company reported a gross margin of 46.49% in 2023, a significant increase of 21.84 percentage points from the previous year, primarily due to the strategic shift away from low-margin real estate operations [21]. Revenue and Profit Forecast - The company anticipates a decline in revenue for 2023, followed by a gradual recovery, with net profit growth projected at +0.2%, +8.8%, and +15.3% for the years 2025 to 2027 [9][41]. Business Segments - The cosmetics segment is expected to see revenue growth of -5%, +6%, and +14% from 2025 to 2027, while the pharmaceutical segment is projected to grow at -5%, -3%, and +5% during the same period [10][41]. - The raw materials and additives segment is forecasted to grow steadily, with revenue increases of +3%, +4%, and +5% from 2025 to 2027 [10]. Competitive Positioning - The company is positioned favorably against comparable domestic brands, with a projected price-to-earnings (P/E) ratio of 28 times for 2026, aligning with industry averages [42]. Marketing and R&D Strategy - The company has invested significantly in R&D, with a budget of RMB 1.16 billion for the first three quarters of 2025, representing a research expense ratio of 4.47% [30]. - New product launches and marketing initiatives are focused on enhancing brand visibility and consumer engagement across various channels, including e-commerce and physical retail [28][34]. Sales Channels - The cosmetics segment's revenue is heavily driven by online sales, contributing 84.2% of total revenue, while offline sales account for 15.8% [34]. - The company is expanding its presence in both online and offline markets, establishing flagship stores on major e-commerce platforms and increasing the number of physical retail locations [34].

Investment Rating - The report maintains a "Buy" rating for the company [3][6] Core Insights - The company is expected to achieve a revenue of 6-7 billion yuan in 2025, representing a year-on-year growth of 410.87% to 496.02%, and a net profit of 1.85-2.15 billion yuan, marking a turnaround from losses [1] - The demand for AI computing power continues to rise, and the maturity of the cloud product line is driving large-scale commercialization across various sectors, including telecommunications, finance, and the internet [1][3] - The company's quarterly revenue is projected to increase, with Q4 2025 revenue estimated between 1.393 billion and 2.393 billion yuan, showing a sequential growth from Q3 2025 [1] Financial Projections - Revenue projections for 2025-2027 are 6.368 billion, 13.091 billion, and 20.953 billion yuan, respectively, with net profits expected to be 2.062 billion, 4.363 billion, and 7.018 billion yuan [3][5] - The company is expected to achieve an EPS of 4.89 yuan in 2025, increasing to 10.35 yuan in 2026 and 16.64 yuan in 2027 [5][10] - The net asset return rate is projected to improve significantly, reaching 18.0% in 2025 and 30.7% in 2027 [5][10] Market Position and Competitive Advantage - The company is positioned in the semiconductor industry, with leading technology in computing chips and accelerated customer adoption, enhancing business resilience and performance [3][6] - The launch of the Cambricon NeuWare software platform supports rapid migration and optimization of AI models, establishing a comprehensive system from self-developed chip architecture to high-performance software [2]

证券研究报告·公司点评报告 2026 年 2 月 3 日 江海证券研究发展部 机械军工行业研究组 执业证书编号：S1410524040001 | 投资评级： | 买入（维持） | | --- | --- | | 当前价格: | 69.37元 | | 市场数据 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 总股本(百万股) | | | 120.76 | | | | | | A 股股本(百万股) | | | 120.76 | | | | | | B/H 股股本(百万股) | | | -/- | | | | | | A 股流通比例(%) | | | 31.25 | | | | | | 个月最高/最低(元) | | | 88.98/36.60 | | 12 | | | | 第一大股东 | | | 蒋修华 | | | | | | 第一大股东持股比例(%) | | | 39.75 | | | | | | 上证综指/沪深 300 | | 4015.75/4605.98 | | | | | | | 数据来源：聚源 | 2 | | 日数据 ...

Investment Rating - The report gives a "Buy" rating for the company, China Jushi (600176.SH), with a current price of 20.15 CNY [2]. Core Views - China Jushi is a leading player in the global fiberglass industry, with a strong focus on innovation and cost advantages. The company has maintained a solid growth trajectory, with significant increases in revenue and net profit over the years [6][14]. - The company is expected to continue its expansion and product high-endization, which will enhance its profitability and growth momentum. The report forecasts revenue growth rates of 20%, 11%, and 10% for 2025, 2026, and 2027, respectively [6][7]. Summary by Sections 1. Company Overview - China Jushi is recognized as a pioneer in the fiberglass industry in China, evolving into a global leader with the largest production capacity for both fiberglass roving and electronic fabrics [14]. - The company has a market share of approximately 34% in the domestic fiberglass sector and 25% in the electronic fabric sector, both ranking first globally [14]. 2. Production Capacity and Innovation - The company has consistently expanded its production capacity, with a focus on high-end products. As of October 2025, it has the largest production capacity for fiberglass roving and electronic fabrics globally [30][31]. - The report highlights that the company has maintained high capital expenditures to support its growth, with production capacity increasing from 210,000 tons in 2004 to 2.74 million tons by the end of 2024 for fiberglass roving [31]. 3. Cost Advantages and Profitability - China Jushi has a significant cost advantage, with its production cost per ton being 1,017 CNY lower than the average of its competitors in 2024. The company has successfully reduced its production costs from 5,888 CNY per ton in 2001 to 3,563 CNY per ton in 2024 [47][51]. - The company's gross margin for fiberglass products is projected to be 24.3% in 2024, which is 9.1 percentage points higher than the average of its competitors [51]. 4. Revenue and Profit Forecast - The report projects that the company's revenue will reach 15.86 billion CNY in 2024, with a year-on-year growth rate of 6.6%. By 2027, revenue is expected to grow to 23.13 billion CNY [2]. - Net profit attributable to shareholders is forecasted to be 2.45 billion CNY in 2024, with a significant increase of 39.3% expected in 2025 [2]. 5. Investment Recommendations - The report emphasizes that the growth potential of China Jushi should not be underestimated, and it recommends a "Buy" rating based on the company's strong market position and ongoing product high-endization efforts [6][7].